MedTrace Logo

A Retrospective Medical Record Review of First-Line Sunitinib Administration Schedules and Outcomes Among Patients With mRCC in Latin America (LA)

NCT04115189 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 57

Last updated 2022-05-10

Study results available
· View outcomes & findings →

Summary

To describe real-world demographic and clinical characteristics, treatment characteristics, and clinical outcomes among patients in Latin America who were treated with first-line sunitinib for metastatic renal cell carcinoma and switched from the 4/2 to 2/1 administration schedule

Conditions

  • Metastatic Renal Cell Carcinoma ( mRCC)

Interventions

DRUG

Sunitinib

Patients to receive Sunitinib as first line therapy for mRCC

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-13
Primary Completion
2020-12-02
Completion
2020-12-02

Countries

  • Argentina
  • Brazil
  • Colombia
  • Ecuador

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04115189 on ClinicalTrials.gov